Navigation Links
FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15
Date:9/15/2010

BOTHELL, Wash., Sept. 15 /PRNewswire/ -- Alder Biopharmaceuticals Inc. today announced FierceBiotech has designated it one of the top private biotech companies and placed it on the annual Fierce 15.

The list, published annually by FierceBiotech, highlights 15 of the top privately held biotech companies out of hundreds of nominees. The list is based on a variety of factors, such as the strength of a company's technology, partnerships and a competitive market position.  A complete list of "Fierce 15" companies is available online at www.fiercebiotech.com.

"The conventional wisdom in biotech holds that startups must always gather up a group of venture backers before they start hiring a crew. But the news must never have made it to CEO Randall Schatzman and his startup team at Alder," said John Carroll, editor of FierceBiotech. "They used their credit cards and borrowed office space to bootstrap Alder before roping in some seed capital. And they never looked back. Partnership cash has helped fund their operations into 2014 as Alder continues to build its reputation in the antibody space and they push through mid-stage development."

Randall Schatzman, Ph.D., president and CEO of Alder, added, "The events of the past 12 months have provided us many opportunities to showcase the hard work of our team, from securing a deal with Bristol-Myers Squibb for nearly $1 billion to reporting Phase 2 data for our lead asset, ALD518, in both cancer and in rheumatoid arthritis. We continue to grow our internal pipeline with highly selective antibody therapeutics and look forward to moving ahead with our clinical-stage programs, including further development on our own of ALD518 in cancer."

About Alder BiopharmaceuticalsAlder Biopharmaceuticals Inc. uniquely identifies, develops and manufactures novel antibody therapeutics to alleviate human suffering in the autoimmune and inflammatory disease areas. Alder's management team combines decades of industry experience with a proven track record for identifying and developing novel antibody therapeutics and enabling partners through the out-licensing of its technologies. In addition to Bristol-Myers Squibb, partners include Merck (Schering-Plough), Seattle Genetics and Genmab. For more information, visit www.alderbio.com.

About FierceBiotechFierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 75,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Sign up is free at http://www.fiercebiotech.com.Media ContactIan Stone or David SchullRusso PartnersTel: +1 619-528-2220ian.stone@russopartnersllc.com david.schull@russopartnersllc.com Heather Cox MartinFierceMarkets, Inc.Tel: +1 202-824-5043heather@fiercemarkets.com
'/>"/>

SOURCE Alder Biopharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FreshFx Recognized for use in the Scalder as a Solution to the Yield/Pathogen Reduction Dilemma
2. Foamix and Galderma to Develop Medicated Foam for Certain Skin Diseases
3. Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis
4. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
5. Galderma Received FDA Approval of Differin(R) (adapalene) Lotion, 0.1%, the First Retinoid Available in Lotion Formulation
6. Herbruck Alder to Convene Summit on the New Healthcare Reform Law
7. Perrigo Confirms Filing for Clobetasol Shampoo and Announcement of Patent Infringement Lawsuit by Galderma
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
11. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... , April 29, 2016  In the next ... to shift from systems dependent on CRTs monitors to ... of modality CRT Medical monitors and will automatically ... a host of foreseeable benefits to this technological ... existing modalities have to be replaced in order ...
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:4/29/2016)... ISELIN, New Jersey , April 29, 2016 ... Omnichannel Software Suite for Life Sciences, Product Development ... and Global Life Science Customer Base . ... healthcare solutions provider, today announced the acquisition of ... is a global leader in adaptive sales enablement ...
Breaking Medicine Technology:
(Date:5/1/2016)... ... ... ProBrand Reveal Volume 2 is a set of versatile and smooth logo reveals built exclusively ... can easily create a unique logo reveal in just a matter of minutes. Custom settings ... title presets to add a uniquely animated logo to any photos or videos. , ProBrand ...
(Date:4/30/2016)... ... April 30, 2016 , ... Create an abstract shape ... distort and manipulate three-dimensional shapes with ease all within Apple Motion . ... polygons, polygon texture animation, opacity texture animation, overall shape texture displacement, twist, camera ...
(Date:4/30/2016)... ... April 30, 2016 , ... Dr. Trevor Gardner, ... EMED, today signed a multifaceted agreement which will allow for the research and ... Department of Natural and Applied Sciences, Allied Health and Nursing will work together ...
(Date:4/29/2016)... ... April 30, 2016 , ... ... products, announces the Pick Up Springboard, an automotive invention that improves the storage ... industry is worth $162 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... the Accreditation Council for Graduate Medical Education (ACGME) that it has received accreditation ... the first accreditation of three residency programs that Memorial is currently pursuing, including ...
Breaking Medicine News(10 mins):